La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

X4 Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

X4 Pharmaceuticals' Il CEO è Paula Ragan, nominato in Jul2014, e ha un mandato di 10.08 anni. la retribuzione annua totale è $ 2.04M, composta da 30.3% di stipendio e 69.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.45% delle azioni della società, per un valore di € 479.53K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 5.4 anni.

Informazioni chiave

Paula Ragan

Amministratore delegato

US$2.0m

Compenso totale

Percentuale dello stipendio del CEO	30.3%
Mandato del CEO	10.2yrs
Proprietà del CEO	0.5%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paula Ragan rispetto agli utili di X4 Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$18m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$2m	US$620k	-US$101m
Sep 30 2023	n/a	n/a	-US$111m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$96m
Dec 31 2022	US$4m	US$583k	-US$96m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$100m
Dec 31 2021	US$2m	US$562k	-US$103m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$82m
Mar 31 2021	n/a	n/a	-US$78m
Dec 31 2020	US$3m	US$543k	-US$62m
Sep 30 2020	n/a	n/a	-US$55m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$2m	US$492k	-US$53m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$921k	US$380k	-US$36m

Compensazione vs Mercato: La retribuzione totale di Paula ($USD 2.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 538.74K ).

Compensazione vs guadagni: La retribuzione di Paula è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Paula Ragan (54 yo)

10.2yrs

Mandato

US$2,044,761

Compensazione

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paula Ragan	CEO, President & Director	10.2yrs	US$2.04m	0.45% $ 448.8k
Adam Mostafa	CFO, Treasurer & Corporate Secretary	6yrs	US$1.15m	Nessun dato
Christophe Arbet-Engels	Chief Medical Officer	1.1yrs	US$1.64m	Nessun dato
Richard Peters	Founder	no data	Nessun dato	Nessun dato
Renato Skerlj	Founder	no data	Nessun dato	Nessun dato
Keith Flaherty	Founder & Member of Corporate Advisory Board	no data	Nessun dato	Nessun dato
Mary DiBiase	Chief Operating Officer	3yrs	US$1.84m	0.17% $ 169.6k
Arthur Taveras	Chief Scientific Officer	3.8yrs	Nessun dato	0.14% $ 137.4k
Robert Arbeit	Senior Vice President of Clinical Development and Translational Research	no data	Nessun dato	Nessun dato
Mark Baldry	Chief Commercial Officer	1.8yrs	Nessun dato	0.015% $ 14.5k

3.4yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di 48Q è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paula Ragan	CEO, President & Director	10.2yrs	US$2.04m	0.45% $ 448.8k
Keith Flaherty	Founder & Member of Corporate Advisory Board	8.4yrs	Nessun dato	Nessun dato
Michael Wyzga	Independent Chairman of the Board	6.2yrs	US$199.34k	0.045% $ 45.0k
Gary Bridger	Director	5.5yrs	US$147.05k	0.031% $ 30.3k
David W. McGirr	Independent Director	7yrs	US$166.05k	0.031% $ 30.3k
Alison Lawton	Independent Director	3.9yrs	US$154.55k	0.031% $ 30.3k
William Aliski	Independent Director	5yrs	US$165.05k	0.031% $ 30.3k
Michael Vasconcelles	Member of Corporate Advisory Board	8.4yrs	Nessun dato	Nessun dato
Robert Woods	Independent Director	less than a year	US$91.83k	Nessun dato
Murray Stewart	Director	5.5yrs	US$90.08k	0.087% $ 85.9k
Francoise de Craecker	Independent Director	2.9yrs	US$152.05k	0.031% $ 30.3k

5.5yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 48Q sono considerati esperti (durata media dell'incarico 5.4 anni).

X4 Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

Director recently sold €125k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

Recent updates

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Now 23% undervalued after recent price drop

Director recently sold €125k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial

New 90-day high: €8.30

Revenue beats expectations

X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor

X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €7.30

New 90-day high: €6.15

X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer

X4 Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of Whim Syndrome

X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer

New 90-day low: €5.00

X4 Pharmaceuticals, Inc. has Re-Assessed the Impacts of the Continuing COVID-19 Pandemic on the Ongoing Phase 1B Dose-Escalation Trial

X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020

New 90-day low - €5.95

New 90-day low - €6.25

X4 Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Growth Index

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media